iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 258.29 Million KRW | -9.8% |
| 2022 | 286.37 Million KRW | -98.22% |
| 2021 | 16.06 Billion KRW | 9119.33% |
| 2020 | 174.27 Million KRW | -99.06% |
| 2019 | 18.51 Billion KRW | 8128.03% |
| 2018 | 224.99 Million KRW | -59.25% |
| 2017 | 552.12 Million KRW | -64.34% |
| 2016 | 1.54 Billion KRW | -11.37% |
| 2015 | 1.74 Billion KRW | 0.0% |
| 2012 | 1.14 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 260.23 Million KRW | 0.0% |
| 2024 Q1 | 294.89 Million KRW | -100.0% |
| 2023 Q3 | 275.34 Million KRW | -3.29% |
| 2023 Q1 | 313.25 Million KRW | 9.39% |
| 2023 FY | 258.29 Million KRW | -9.8% |
| 2023 Q2 | 284.72 Million KRW | -9.11% |
| 2023 Q4 | 258.29 Million KRW | -6.19% |
| 2022 FY | 286.37 Million KRW | -98.22% |
| 2022 Q4 | 286.37 Million KRW | 8.55% |
| 2022 Q3 | 263.81 Million KRW | -98.51% |
| 2022 Q2 | 17.67 Billion KRW | 4.81% |
| 2022 Q1 | 16.86 Billion KRW | 4.99% |
| 2021 Q3 | 15.24 Billion KRW | 17619.03% |
| 2021 Q4 | 16.06 Billion KRW | 5.38% |
| 2021 FY | 16.06 Billion KRW | 9119.33% |
| 2021 Q1 | 120.49 Million KRW | -30.86% |
| 2021 Q2 | 86.05 Million KRW | -28.59% |
| 2020 FY | 174.27 Million KRW | -99.06% |
| 2020 Q1 | 14.37 Billion KRW | 2.03% |
| 2020 Q4 | 174.27 Million KRW | -25.87% |
| 2020 Q3 | 235.09 Million KRW | -98.21% |
| 2020 Q2 | 13.15 Billion KRW | -8.49% |
| 2019 Q3 | 13.8 Billion KRW | 1.72% |
| 2019 FY | 18.51 Billion KRW | 8128.03% |
| 2019 Q1 | 711.77 Million KRW | 216.35% |
| 2019 Q4 | 14.09 Billion KRW | 2.08% |
| 2019 Q2 | 13.56 Billion KRW | 1806.48% |
| 2018 Q4 | 224.99 Million KRW | -26.66% |
| 2018 FY | 224.99 Million KRW | -59.25% |
| 2018 Q3 | 306.77 Million KRW | -21.05% |
| 2018 Q2 | 388.55 Million KRW | -17.39% |
| 2018 Q1 | 470.34 Million KRW | -14.81% |
| 2017 Q1 | 797.47 Million KRW | -48.49% |
| 2017 FY | 552.12 Million KRW | -64.34% |
| 2017 Q4 | 552.12 Million KRW | -12.9% |
| 2017 Q3 | 633.9 Million KRW | -11.43% |
| 2017 Q2 | 715.68 Million KRW | -10.26% |
| 2016 Q4 | 1.54 Billion KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 FY | 1.54 Billion KRW | -11.37% |
| 2015 FY | 1.74 Billion KRW | 0.0% |
| 2013 Q3 | 462.68 Million KRW | -16.58% |
| 2013 Q2 | 554.63 Million KRW | -54.24% |
| 2013 Q1 | 1.21 Billion KRW | 5.66% |
| 2012 FY | 1.14 Billion KRW | 0.0% |
| 2012 Q4 | 1.14 Billion KRW | -10.75% |
| 2012 Q3 | 1.28 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 17.93 Billion KRW | 98.56% |
| BINEX Co., Ltd. | 5.57 Billion KRW | 95.37% |
| Bioneer Corporation | 12.5 Billion KRW | 97.934% |
| Anterogen.Co.,Ltd. | - KRW | -Infinity% |
| MEDIPOST Co., Ltd. | 6.99 Billion KRW | 96.307% |
| CrystalGenomics, Inc. | 29.88 Billion USD | 99.136% |
| Helixmith Co., Ltd | 151.68 Million KRW | -70.289% |
| Chabiotech Co.,Ltd. | 95.06 Billion KRW | 99.728% |
| Medy-Tox Inc. | 1.22 Billion KRW | 78.929% |
| Peptron, Inc. | 4.5 Billion KRW | 94.26% |
| Amicogen, Inc. | 70.65 Billion KRW | 99.634% |
| Genexine, Inc. | 22.68 Billion KRW | 98.861% |
| HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | 85.964% |
| LegoChem Biosciences, Inc. | 528.37 Million KRW | 51.115% |
| ALTEOGEN Inc. | 1.24 Billion KRW | 79.324% |
| PharmaResearch Co., Ltd. | 970.71 Million KRW | 73.391% |
| SillaJen, Inc. | 8.13 Billion KRW | 96.825% |
| JETEMA, Co., Ltd. | 60 Billion KRW | 99.57% |
| OliX Pharmaceuticals,Inc | 35.36 Billion KRW | 99.27% |
| Genomictree Inc. | 97.51 Million KRW | -164.875% |
| MedPacto, Inc. | 1.68 Billion KRW | 84.689% |
| D&D Pharmatech | 5.12 Billion KRW | 94.956% |
| EASY BIO,Inc. | 30 Billion KRW | 99.139% |
| GI Innovation, Inc. | 2.9 Billion KRW | 91.106% |